BackTable / Tumor Board / Podcast / Episode #27

Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology

with Dr. Tyler Stewart

With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who’s on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer.

This podcast is supported by:

Ferring Pharmaceuticals

Be part of the conversation. Put your sponsored messaging on this episode. Learn how.

Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology with Dr. Tyler Stewart on the BackTable Tumor Board Podcast

Ep 27 Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology with Dr. Tyler Stewart

00:00 / 01:04

BackTable, LLC (Producer). (2025, October 7). Ep. 27 – Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology [Audio podcast]. Retrieved from https://www.backtable.com

Stay Up To Date

Follow:

Subscribe:

Podcast Contributors

Dr. Bogdana Schmidt

Dr. Bogdana Schmidt, MD, MPH, is a urologic surgeon specializing in urologic oncology at the University of Utah in Salt Lake City, Utah.

Dr. Tyler Stewart

Dr. Tyler Stewart is a medical oncologist and associate professor at UC San Diego Health in California.

Synopsis

The conversation covers the efficacy and safety of checkpoint inhibitors like pembrolizumab, the importance of a multidisciplinary approach, and the challenges of balancing systemic and localized treatments. They also touch upon the potential future role of biomarkers in reducing invasive procedures and improving patient outcomes.

Timestamps

00:00 - Introduction
02:04 - The Role of Medical Oncologists in Bladder Cancer
12:58 - Combination Therapies and Patient Outcomes
21:18 - The CREST Study
26:59 - Managing Adverse Events
34:44 - Collaboration Between Urologists and Oncologists
41:06 - Conclusion and Final Thoughts

Resources

CREST Trial
https://www.nature.com/articles/s41591-025-03738-z

CISTO Study
https://pubmed.ncbi.nlm.nih.gov/37980511/

The Materials available on BackTable are for informational and educational purposes only and are not a substitute for the professional judgment of a healthcare professional in diagnosing and treating patients. The opinions expressed by participants of the BackTable Podcast belong solely to the participants, and do not necessarily reflect the views of BackTable.

Up Next

Lung Cancer Staging & Systemic Therapies: Recent Advancements with Dr. Karen Reckamp and Dr. Scott Atay on the BackTable Tumor Board Podcast

NSCLC Tumor Board Discussion: Considerations for Oligometastatic Disease with Dr. Karen Reckamp, Dr. Scott Atay, Dr. Scott Oh, Dr. Alan Lee and Dr. Scott Genshaft on the BackTable Tumor Board Podcast

Keynote-689: Implementation & Multidisciplinary Care for Immunotherapy in Head & Neck Cancer with Dr. Adam Luginbuhl, Dr. Jennifer Johnson, Dr. Mihir Patel and Dr. Siddharth Sheth on the BackTable Tumor Board Podcast

Understanding Keynote-689: Immunotherapy for Head & Neck Cancer with Dr. Dylan Roden, Dr. Ravi Uppaluri and Dr. Adam Luginbuhl on the BackTable Tumor Board Podcast

Penile Cancer Management: Insights & Case Studies with Dr. Juanita Crook and Dr. Andrea Apolo on the BackTable Tumor Board Podcast

Complex HCC Patients & The "Grey Zone": What To Do When You Don’t Know What To Do with Dr. Adam Burgoyne, Dr. Zach Berman, Dr. Kirema Garcia-Reyes and Dr. Lingling Du on the BackTable Tumor Board Podcast

Articles

Topics

Get in touch!

We want to hear from you. Let us know if you’re interested in partnering with BackTable as a Podcast guest, a sponsor, or as a member of the BackTable Team.